Company Overview and News
SINGAPORE: National carrier Singapore Airlines (SIA) on Thursday (May 17) topped market expectations by reporting a 148 per cent rise in full-year net profit to the highest level since 2011, as passenger and cargo revenue rose and it benefited from a transformation programme.
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
JetBlue Airways Corporation (JBLU - Free Report) posted a rise in traffic figures for April. Traffic — measured in revenue passenger miles (RPMs) — improved 5.7% year over year to 4.3 billion. On a year-over-year basis, consolidated capacity (or available seat miles/ASMs) expanded 5.3% to 5.02 billion. Load factor or percentage of seats filled by passengers increased 40 basis points (bps) to 85.7% in the month as traffic growth outpaced capacity expansion.
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
Southwest Airlines Co. (LUV - Free Report) reported disappointing traffic results for April. Traffic (measured in revenue passenger miles or RPMs) slipped 0.3% to around 11.2 billion while capacity or available seat miles (ASMs) inched up 1.5% to 13.57 billion. The decline in traffic is due to softness in bookings following the fatal engine failure last month. Also, load factor (percentage of seats filled by passengers) deteriorated 150 basis points (bps) to 82.
United Continental Holdings, Inc.’s (UAL - Free Report) wholly owned subsidiary, United Airlines, reported dismal traffic figures for April. Consolidated traffic, measured in revenue passenger miles (RPMs), was 18.47 billion, up 5.1% from the year-ago figure. On a year-over-year basis, consolidated capacity (or available seat miles/ASMs) climbed 6.1% to 22.43 billion. However, load factor (percentage of seats occupied by passengers) declined 80 basis points (bps) to 82.
Hawaiian Holdings, Inc.’s (HA - Free Report) wholly owned subsidiary, Hawaiian Airlines, reported traffic figures for April. Traffic (measured in Revenue Passenger Miles or RPMs) increased 7.1% to around 1.39 billion in April. Available Seat Miles (ASMs) also climbed 7.3% to 1.63 billion in the month. However, load factor (percentage of seats filled by passengers) declined 10 basis points (bps) to 85.
Gol Linhas Aereas Inteligentes S.A. (GOL - Free Report) reported air traffic figures for April. Consolidated traffic, measured in revenue passenger kilometers (RPK), nudged up 1.9% to 2.76 billion. The metric rose 3% on the domestic front while the international figure declined 7.2%. On a year-over-year basis, consolidated capacity (or available seat kilometers/ASKs) inched up 0.8% to 3.46 billion, primarily on the back of 1.
C.H. Robinson Worldwide Inc.’s (CHRW - Free Report) first-quarter 2018 earnings per share of $1.01 beat the Zacks Consensus Estimate of 99 cents. Moreover, the bottom line improved 17.4% year over year on higher revenues and lower tax rate Total revenues rose 14.9% year over year to $3,925.3 million, surpassing the Zacks Consensus Estimate of $3,808.8 million.
BEIJING—Hainan Airlines will step up development of intercontinental business at Shenzhen, making the rich southern Chinese city its second long-haul base, after Beijing, sources close to the company said. The move will increase competitive pressure on China Southern Airlines, the dominant operator at Guangzhou, 100 km (60 mi.) away, and on Cathay Pacific Airways, based next to Shenzhen at Hong Kong.
In a bid to improve efficiency, Kansas City Southern (KSU - Free Report) has partnered with CloudMoyo to enhance its railroad operating system. The CloudMoyo Rail Transportation Management (CRTM) system will be roped in for the task. The CRTM built on CloudMoyo Transportation platform, is a next-generation system leveraging the scale of the Microsoft Azure cloud. This cloud-based solution will use analytics and artificial intelligence to improve operational performance and agility.
American Airlines Group Inc. (AAL - Free Report) has its share of positives, despite the prevalent negative sentiment due to rising fuel costs. On the flip side, with the metric persistently increasing and eating into the company’s profits, it is likely that the carrier will pass on the high-cost burden to passengers’ pockets. Notably, during first-quarter 2018 earnings release, American Airlines CEO warned of rising air fares in the near future, which bodes well for airline companies in boosting the top line.
United Parcel Service, Inc. (UPS - Free Report) reported first-quarter 2018 earnings of $1.55, beating the Zacks Consensus Estimate of $1.54 per share. The bottom line also increased 17.4% on a year-over-year basis. Results were aided by strong performances from the International and Supply Chain and Freight segments. Revenues improved 10% to $17,113 million from the year-ago quarter, outpacing the Zacks Consensus Estimate of $16,443.
Southwest Airlines Co. (LUV - Free Report) reported first-quarter 2018 earnings per share (excluding 4 cents from non-recurring items) of 75 cents, in line with the Zacks Consensus Estimate. The bottom line however, surged on a year-over-year basis. Operating revenues of $4,944 million lagged the Zacks Consensus Estimate of $5,017.6 million. However, the top line improved year over year and was boosted by high passenger revenues accounting for bulk (92.
Allegiant Travel Company (ALGT - Free Report) reported first-quarter earnings of $3.42 per share, well above the Zacks Consensus Estimate of $3. Also, the bottom line improved significantly on a year-over-year basis. Results were aided by the strong demand for air travel. Quarterly revenues increased in double-digits year over year to $425.4 million, marginally above the Zacks Consensus Estimate of $425.
2018-05-19 - Asif
OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...
2018-05-19 - Asif
Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...
2018-05-17 - Asif
Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...